188 related articles for article (PubMed ID: 33611224)
1. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
Friedes C; Chakrabarti T; Olson S; Prichett L; Brahmer JR; Forde PM; Voong RK; Marrone KA; Lam VK; Hann CL; Broderick SR; Battafarano RJ; Ha JS; Bush EL; Yang SC; Hales RK; Feliciano JL
Lung Cancer; 2021 Apr; 154():36-43. PubMed ID: 33611224
[TBL] [Abstract][Full Text] [Related]
2. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
Liu Y; Zhang Z; Rinsurongkawong W; Gay CM; Le X; Ning MS; Lewis J; Rinsurongkawong V; Lee JJ; Roth J; Swisher S; Gandhi S; Lee PP; Gibbons DL; Vaporciyan AA; Heymach JV; Zhang J; Lin SH
JAMA Netw Open; 2022 Jun; 5(6):e2215589. PubMed ID: 35666500
[TBL] [Abstract][Full Text] [Related]
3. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC.
Friedes C; Iocolano M; Lee SH; Duan L; Li B; Doucette A; Cohen RB; Aggarwal C; Sun LL; Levin WP; Cengel KA; Kao G; Teo BK; Langer CJ; Xiao Y; Bradley J; Feigenberg SJ; Yegya-Raman N
Radiother Oncol; 2024 Jan; 190():110030. PubMed ID: 38008414
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.
Lebow ES; Shepherd A; Eichholz JE; Offin M; Gelblum DY; Wu AJ; Simone CB; Schoenfeld AJ; Jones DR; Rimner A; Chaft JE; Riaz N; Gomez DR; Shaverdian N
JAMA Netw Open; 2023 Jan; 6(1):e2249591. PubMed ID: 36602799
[TBL] [Abstract][Full Text] [Related]
5. Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer.
Cho Y; Park S; Byun HK; Lee CG; Cho J; Hong MH; Kim HR; Cho BC; Kim S; Park J; Yoon HI
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1065-1073. PubMed ID: 31476418
[TBL] [Abstract][Full Text] [Related]
6. Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases.
Li YD; Lamano JB; Kaur G; Lamano JB; Veliceasa D; Biyashev D; Kruser T; Bloch O
J Neurooncol; 2019 Jun; 143(2):337-347. PubMed ID: 30982197
[TBL] [Abstract][Full Text] [Related]
7. Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yang G; Yoon HI; Lee J; Kim J; Kim H; Cho J; Lee CG; Chang JS; Cho Y; Kim JS; Kim KH
Radiother Oncol; 2023 Dec; 189():109934. PubMed ID: 37783291
[TBL] [Abstract][Full Text] [Related]
8. Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.
Zhao Q; Chen G; Ye L; Shi S; Du S; Zeng Z; He J
Radiat Oncol; 2019 May; 14(1):86. PubMed ID: 31133034
[TBL] [Abstract][Full Text] [Related]
9. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.
Wild AT; Ye X; Ellsworth SG; Smith JA; Narang AK; Garg T; Campian J; Laheru DA; Zheng L; Wolfgang CL; Tran PT; Grossman SA; Herman JM
Am J Clin Oncol; 2015 Jun; 38(3):259-65. PubMed ID: 23648440
[TBL] [Abstract][Full Text] [Related]
10. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
11. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
12. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy.
Chen D; Patel RR; Verma V; Ramapriyan R; Barsoumian HB; Cortez MA; Welsh JW
Radiother Oncol; 2020 Sep; 150():114-120. PubMed ID: 32525003
[TBL] [Abstract][Full Text] [Related]
13. Lymphopenia association with accelerated hyperfractionation and its effects on limited-stage small cell lung cancer patients' clinical outcomes.
Wang X; Lu J; Teng F; Yu J
Ann Transl Med; 2019 Aug; 7(16):385. PubMed ID: 31555699
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.
Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y
J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma.
Yin T; Wang P; Yu J; Teng F
Int Immunopharmacol; 2022 May; 106():108623. PubMed ID: 35203044
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
[TBL] [Abstract][Full Text] [Related]
17. [A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
Liu Y; Zhang T; Gao Y; Qu Y; Lu B; Zhang H; Wang Q; Li J; Hu F; Li B
Zhongguo Fei Ai Za Zhi; 2019 Nov; 22(11):687-695. PubMed ID: 31771737
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.
Cho Y; Kim Y; Chamseddine I; Lee WH; Kim HR; Lee IJ; Hong MH; Cho BC; Lee CG; Cho S; Kim JS; Yoon HI; Grassberger C
Radiother Oncol; 2022 Mar; 168():1-7. PubMed ID: 35033601
[TBL] [Abstract][Full Text] [Related]
19. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?
Chadha AS; Liu G; Chen HC; Das P; Minsky BD; Mahmood U; Delclos ME; Suh Y; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH; Wang X; Thames H; Krishnan S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):323-332. PubMed ID: 28068240
[TBL] [Abstract][Full Text] [Related]
20. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.
Sun L; Bleiberg B; Hwang WT; Marmarelis ME; Langer CJ; Singh A; Cohen RB; Mamtani R; Aggarwal C
JAMA Oncol; 2023 Aug; 9(8):1075-1082. PubMed ID: 37270700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
